Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Cell-line-specific stimulation of tumor cell aggressiveness by wound healing factors – a central role for STAT3

Authors: Lars Ekblad, Gustaf Lindgren, Emma Persson, Elisabeth Kjellén, Johan Wennerberg

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Local recurrence is a major factor affecting survival after treatment for head and neck squamous cell carcinoma (HNSCC). It is possible that the normal processes involved in wound healing after surgical removal of a primary tumor can boost the regrowth of residual cancer cells, thereby contributing to the recurrent growth. In this work, we collected human wound fluids and used them to investigate the effect of wound healing factors on HNSCC cell lines in vitro.

Methods

Wound fluids were collected from thyroidectomized patients diagnosed with benign disease and were included in assays of cell proliferation, migration, cell scattering, and invasion. The involvement of intracellular signaling pathways and membrane receptors were investigated by western blotting and the inclusion of specific inhibitors.

Results

One out of four cell lines was greatly stimulated in proliferation, migration, cell scattering, and invasion by the addition of wound fluid as compared with addition of fetal bovine or human serum. These effects were accompanied by a sharp increase in activation of signal transducer and activator of transcription 3 (STAT3). Inhibition of STAT3 activation abolished the wound fluid response, showing that STAT3 plays an important role in the wound healing response. Several of the observed phenotypic changes were epithelial-to-mesenchymal transition (EMT)-like, but the appropriate changes were not seen in any of the EMT markers investigated. The involvement of c-Met or epidermal growth factor receptor family members was excluded, while the interleukin-6 receptor was found to be partly responsible for the activation of STAT3.

Conclusions

In conclusion, we found cell-line-specific effects of wound healing factors on HNSCC, setting the stage for therapy development and predictive opportunities.
Appendix
Available only for authorised users
Literature
1.
2.
Braakhuis BJ, Bloemena E, Leemans CR, Brakenhoff RH: Molecular analysis of surgical margins in head and neck cancer: More than a marginal issue. Oral Oncol. 2010, 46 (7): 485-491. 10.1016/j.oraloncology.2010.01.019.CrossRefPubMed
3.
4.
Lundberg O, Kristoffersson A: Wound recurrence from gallbladder cancer after open cholecystectomy. Surgery. 2000, 127 (3): 296-300. 10.1067/msy.2000.104487.CrossRefPubMed
5.
Abramovitch R, Marikovsky M, Meir G, Neeman M: Stimulation of tumour growth by wound-derived growth factors. Br J Cancer. 1999, 79 (9/10): 1392-1398. 10.1038/sj.bjc.6690223.CrossRefPubMedPubMedCentral
6.
Baker DG, Masterson TM, Pace R, Constable WC, Wanebo H: The influence of the surgical wound on local tumor recurrence. Surgery. 1989, 106 (3): 525-532.PubMed
7.
Bogden AE, Moreau JP, Eden PA: Proliferative response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition. Br J Cancer. 1997, 75 (7): 1021-1027. 10.1038/bjc.1997.175.CrossRefPubMedPubMedCentral
8.
Hofer SOP, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ: Wound-Induced Tumor Progression: A Probable Role in Recurrence After Tumor Resection. Arch Surg. 1998, 133 (4): 383-389. 10.1001/archsurg.133.4.383.CrossRefPubMed
9.
Lee JY, Murphy SM, Scanlon EF: Effect of trauma on implantation of metastatic tumor in bone in mice. J Surg Oncol. 1994, 56 (3): 178-184. 10.1002/jso.2930560311.CrossRefPubMed
10.
Murthy SM, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T, Scanlon EF: The influence of surgical trauma on experimental metastasis. Cancer. 1989, 64 (10): 2035–2044-2044.CrossRefPubMed
11.
Rho O, Kim DJ, Kiguchi K, Digiovanni J: Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog. 2011, 50 (4): 264-279. 10.1002/mc.20665.CrossRefPubMed
12.
Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, et al: Role of HER2 in wound-induced breast carcinoma proliferation. Lancet. 2003, 362 (9383): 527-533. 10.1016/S0140-6736(03)14112-8.CrossRefPubMed
13.
Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, et al: Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol. 2011, 22 (8): 1886-1893. 10.1093/annonc/mdq756.CrossRefPubMed
14.
Roh J-L, Sung M-W, Kim KH: Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin. Head Neck. 2005, 27 (4): 326-332. 10.1002/hed.20167.CrossRefPubMed
15.
Cohen HJ, Laszlo J: Influence of trauma on the unusual distribution of metastases from carcinoma of the larynx. Cancer. 1972, 29 (2): 466-471. 10.1002/1097-0142(197202)29:2<466::AID-CNCR2820290234>3.0.CO;2-M.CrossRefPubMed
16.
Walter ND, Rice PL, Redente EF, Kauvar EF, Lemond L, Aly T, Wanebo K, Chan ED: Wound healing after trauma may predispose to lung cancer metastasis: review of potential mechanisms. Am J Respir Cell Mol Biol. 2011, 44 (5): 591-596. 10.1165/rcmb.2010-0187RT.CrossRefPubMed
17.
Henriksson E, Baldetorp B, Borg Å, Kjellén E, Åkervall J, Wennerberg J, Wahlberg P: p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol. 2006, 45 (3): 300-305. 10.1080/02841860600547380.CrossRefPubMed
18.
Henriksson E, Kjellén E, Baldetorp B, Bendahl PO, Borg Å, Brun E, Mertens F, Ohlsson T, Rennstam K, Wennerberg J, et al: Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck. J Exp Clin Cancer Res. 2009, 28: 17-10.1186/1756-9966-28-17.CrossRefPubMedPubMedCentral
19.
Oshima G, Wennerberg J, Yamatodani T, Kjellen E, Mineta H, Johnsson A, Ekblad L: Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol. 2012, 138 (3): 491-499. 10.1007/s00432-011-1127-5.CrossRefPubMed
20.
21.
Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H, Wennerberg J: Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol. 2009, 135 (3): 395-402. 10.1007/s00432-008-0475-2.CrossRefPubMed
22.
Welinder C, Ekblad L: Coomassie staining as loading control in Western blot analysis. J Proteome Res. 2011, 10 (3): 1416-1419. 10.1021/pr1011476.CrossRefPubMed
23.
24.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003, 4 (12): 915-925. 10.1038/nrm1261.CrossRefPubMed
25.
Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM: Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998, 391 (6664): 285-288. 10.1038/34657.CrossRefPubMed
26.
Zhang YW, Wang LM, Jove R, Vande Woude GF: Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene. 2002, 21 (2): 217-226. 10.1038/sj.onc.1205004.CrossRefPubMed
27.
Roh JL, Sung MW, Kim KH: Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin. Head Neck. 2005, 27 (4): 326-332. 10.1002/hed.20167.CrossRefPubMed
28.
Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2 (6): 442-454. 10.1038/nrc822.CrossRefPubMed
29.
Holstein SA, Hohl RJ: Therapeutic additions and possible deletions in oncology in 2011. Clin Pharmacol Ther. 2012, 91 (1): 15-17. 10.1038/clpt.2011.288.CrossRefPubMed
30.
Werner S, Grose R: Regulation of Wound Healing by Growth Factors and Cytokines. Physiol Rev. 2003, 83 (3): 835-870.PubMed
31.
Conway K, Price P, Harding KG, Jiang WG: The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen. 2006, 14 (1): 2-10. 10.1111/j.1524-475X.2005.00081.x.CrossRefPubMed
32.
Hodge DR, Hurt EM, Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005, 41 (16): 2502-2512. 10.1016/j.ejca.2005.08.016.CrossRefPubMed
33.
Chakravarti N, Myers JN, Aggarwal BB: Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer. 2006, 119 (6): 1268-1275. 10.1002/ijc.21967.CrossRefPubMed
34.
Pries R, Thiel A, Brocks C, Wollenberg B: Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo. 2006, 20 (1): 45-48.PubMed
35.
Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN: Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008, 113 (4): 750-757. 10.1002/cncr.23615.CrossRefPubMed
36.
Kermorgant S, Parker PJ: Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol. 2008, 182 (5): 855-863. 10.1083/jcb.200806076.CrossRefPubMedPubMedCentral
37.
Metadata
Title
Cell-line-specific stimulation of tumor cell aggressiveness by wound healing factors – a central role for STAT3
Authors
Lars Ekblad
Gustaf Lindgren
Emma Persson
Elisabeth Kjellén
Johan Wennerberg
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-33

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer

Research article

Can selenium levels act as a marker of colorectal cancer risk?

Research article

Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Study protocol

Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial

Research article

Urinary incontinence and health-related quality of life among older Americans with and without cancer: a cross-sectional study

Research article

Annexin A7 suppresses lymph node metastasis of hepatocarcinoma cells in a mouse model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits